Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer
BACKGROUND Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their si...
Saved in:
Published in: | The Prostate Vol. 69; no. 13; pp. 1387 - 1397 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
15-09-2009
Wiley-Liss |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | BACKGROUND
Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored. The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma.
METHODS
To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry. Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU‐145.
RESULTS
TLR4 is expressed in the normal prostate gland in both stroma and epithelium. TLR4 expression significantly drops to negative values as the Gleason grade augments in both, stroma and epithelium. Moreover, DU‐145 cells also exhibit TLR4 expression and respond to TLR4 agonists, activating the transcription factor NF‐κB and increasing the expression of pro‐inflammatory mediators. Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant‐negative mutants diminished LPS‐induced activation of NF‐κB, showing that DU‐145 cells activate the NF‐κB through MyD88‐dependent signaling pathways.
CONCLUSIONS
We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis. Prostate 69: 1387–1397, 2009. © 2009 Wiley‐Liss, Inc. |
---|---|
AbstractList | BACKGROUND
Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored. The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma.
METHODS
To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry. Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU‐145.
RESULTS
TLR4 is expressed in the normal prostate gland in both stroma and epithelium. TLR4 expression significantly drops to negative values as the Gleason grade augments in both, stroma and epithelium. Moreover, DU‐145 cells also exhibit TLR4 expression and respond to TLR4 agonists, activating the transcription factor NF‐κB and increasing the expression of pro‐inflammatory mediators. Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant‐negative mutants diminished LPS‐induced activation of NF‐κB, showing that DU‐145 cells activate the NF‐κB through MyD88‐dependent signaling pathways.
CONCLUSIONS
We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis. Prostate 69: 1387–1397, 2009. © 2009 Wiley‐Liss, Inc. Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll-like receptors (TLRs) compose a family of receptors mainly expressed on immune cells. Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored. The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma. To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry. Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU-145. TLR4 is expressed in the normal prostate gland in both stroma and epithelium. TLR4 expression significantly drops to negative values as the Gleason grade augments in both, stroma and epithelium. Moreover, DU-145 cells also exhibit TLR4 expression and respond to TLR4 agonists, activating the transcription factor NF-kappaB and increasing the expression of pro-inflammatory mediators. Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant-negative mutants diminished LPS-induced activation of NF-kappaB, showing that DU-145 cells activate the NF-kappaB through MyD88-dependent signaling pathways. We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis. Prostate 69: 1387-1397, 2009. (c) 2009 Wiley-Liss, Inc. |
Author | Masini-Repiso, Ana Maria Rivero, Virginia E. Gatti, Gerardo Maldonado, Cristina A. Maccioni, Mariana Quintar, Amado A. Andreani, Virginia Nicola, Juan P. |
Author_xml | – sequence: 1 givenname: Gerardo surname: Gatti fullname: Gatti, Gerardo organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina – sequence: 2 givenname: Amado A. surname: Quintar fullname: Quintar, Amado A. organization: Centro de Microscopía Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina – sequence: 3 givenname: Virginia surname: Andreani fullname: Andreani, Virginia organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina – sequence: 4 givenname: Juan P. surname: Nicola fullname: Nicola, Juan P. organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina – sequence: 5 givenname: Cristina A. surname: Maldonado fullname: Maldonado, Cristina A. organization: Centro de Microscopía Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina – sequence: 6 givenname: Ana Maria surname: Masini-Repiso fullname: Masini-Repiso, Ana Maria organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina – sequence: 7 givenname: Virginia E. surname: Rivero fullname: Rivero, Virginia E. organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina – sequence: 8 givenname: Mariana surname: Maccioni fullname: Maccioni, Mariana email: mmaccioni@bioclin.fcq.unc.edu.ar organization: Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21831154$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19496069$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE9T2zAQxTUdmCahvfABGF24dMZUsmTLOjKQhnZC6UBajhpFWoHA2EYSf_Lta5M03HrY2cvvvbf7JminaRtAaJ-SI0pI_rULbTzKiaz4BzSmRIqMEF7soDHJBck4ZWKEJjHeEdLjJP-IRlRyWZJSjtHj9LULEKNvG9w6vGjrOqv9PeAABrrUBsyxb3C6BTzEJJ0A39S6sXgYnyLWMbbG6zQ4vPh0-8ZGeIbg02rw3OqMbgyET2jX6TrC583eQ7-_TRcnZ9n8Yvb95HieGSYLntkScqm1qbSlS8uEdA44s2C0FaRgUhu6FKANOFNKcFxUhbWGs5KKpbOVYXvoy9rX9PkxgFNd8A86rBQlauhNDYept956-GANd0_LB7Dv6KaoHjjcADoaXbvQ_-LjlstpxSgtBiO65l58Dav_RKpflxdX_8KztcbHBK9bjQ73qhRMFOr650xdnc9P6eWPP-qM_QW00Joa |
CODEN | PRSTDS |
CitedBy_id | crossref_primary_10_1016_j_tips_2016_06_010 crossref_primary_10_1007_s10620_021_06973_9 crossref_primary_10_1136_jclinpath_2011_200402 crossref_primary_10_1002_pros_21150 crossref_primary_10_1158_0008_5472_CAN_10_2210 crossref_primary_10_3347_PHD_22160 crossref_primary_10_3892_ijo_2014_2479 crossref_primary_10_1016_j_micres_2023_127596 crossref_primary_10_17650_2070_9781_2022_23_3_41_47 crossref_primary_10_3390_cancers6021065 crossref_primary_10_1016_j_bbcan_2012_10_006 crossref_primary_10_3390_ijms16034471 crossref_primary_10_1016_j_anireprosci_2011_03_008 crossref_primary_10_4161_onci_22089 crossref_primary_10_1017_S0007114511007227 crossref_primary_10_1371_journal_pone_0197327 crossref_primary_10_1371_journal_pone_0016205 crossref_primary_10_1007_s00251_012_0674_5 crossref_primary_10_5213_inj_2014_18_1_10 crossref_primary_10_1002_pros_21423 crossref_primary_10_1016_j_canlet_2012_01_040 crossref_primary_10_3109_10520295_2013_785592 crossref_primary_10_3892_or_2023_8560 crossref_primary_10_1016_j_canlet_2015_08_004 crossref_primary_10_1371_journal_pone_0179897 crossref_primary_10_1186_s13058_021_01418_7 crossref_primary_10_3390_ph3103127 crossref_primary_10_1002_pros_21115 crossref_primary_10_1007_s00018_011_0864_6 crossref_primary_10_1002_pros_23655 crossref_primary_10_1016_j_prp_2024_155379 crossref_primary_10_1002_pbc_24211 crossref_primary_10_1530_REP_11_0163 crossref_primary_10_3389_fimmu_2014_00352 crossref_primary_10_3389_fimmu_2022_941667 crossref_primary_10_1016_j_urology_2017_09_026 crossref_primary_10_1016_j_jri_2013_05_002 crossref_primary_10_1111_j_1365_2605_2012_01288_x crossref_primary_10_1007_s11912_024_01520_x crossref_primary_10_1007_s11154_023_09838_w crossref_primary_10_1099_jmm_0_024877_0 crossref_primary_10_1038_nrurol_2017_167 crossref_primary_10_1007_s40291_018_0361_9 crossref_primary_10_1016_j_bbadis_2012_09_002 crossref_primary_10_1002_cbin_10755 crossref_primary_10_1007_s00345_011_0690_3 crossref_primary_10_1016_j_oooo_2020_01_001 crossref_primary_10_1016_j_mcp_2014_01_006 crossref_primary_10_4103_jcrt_jcrt_2032_21 crossref_primary_10_1155_2011_609579 crossref_primary_10_4142_jvs_2015_16_3_281 crossref_primary_10_1152_physrev_00021_2019 |
Cites_doi | 10.1097/01.ju.0000108131.43160.77 10.4049/jimmunol.172.2.1256 10.4049/jimmunol.178.5.3186 10.1128/IAI.00593-06 10.1093/jnci/85.3.200 10.1111/j.1525-1438.2007.01008.x 10.1189/jlb.1005597 10.1097/MOU.0b013e3282f9b3b7 10.1038/ni1112 10.1038/sj.onc.1210911 10.1073/pnas.92.10.4337 10.3322/canjclin.49.1.8 10.1074/jbc.M305536200 10.1111/j.1464-410X.2007.07091.x 10.1158/0008-5472.CAN-05-2078 10.1093/jnci/dji070 10.1227/01.NEU.0000249280.61761.2E 10.1095/biolreprod.106.053967 10.1023/A:1020110718701 10.1159/000151602 10.1002/mc.20325 10.1084/jem.20070325 10.1146/annurev.immunol.21.120601.141126 10.1002/pros.10317 10.4049/jimmunol.174.9.5781 10.1038/sj.onc.1210904 10.1097/00001648-200201000-00012 10.1016/j.urology.2004.12.028 10.4049/jimmunol.168.3.1435 10.1128/JCM.37.6.1863-1870.1999 10.1128/IAI.73.2.687-694.2005 10.1038/nri2079 10.1016/j.molimm.2007.01.022 10.1158/0008-5472.CAN-03-3280 10.1158/1055-9965.EPI-06-0429 10.1158/0008-5472.CAN-07-0079 10.1038/nrc2090 10.1002/pros.20562 10.1038/ni1569 |
ContentType | Journal Article |
Copyright | Copyright © 2009 Wiley‐Liss, Inc. 2009 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2009 Wiley‐Liss, Inc. – notice: 2009 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1002/pros.20984 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0045 |
EndPage | 1397 |
ExternalDocumentID | 10_1002_pros_20984 19496069 21831154 PROS20984 ark_67375_WNG_SMLD1RJV_H |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET) funderid: PEI 6557 – fundername: Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT) funderid: PICT 2002 11944; PICT 2006 02369 |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAMNL AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ TEORI UB1 V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT .GJ 3O- AAVGM ABEML ABHUG ABWRO ACSCC ACXME ADAWD ADDAD AFFNX AFVGU AGJLS EBD EMOBN IQODW M6P PALCI RIWAO RJQFR SAMSI SV3 ZA5 ZGI ZXP CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c3954-d6e29aac8ad1bd379ffe43decad70539ac1b7eacefc69ef4785ddc43617bfd8c3 |
IEDL.DBID | 33P |
ISSN | 0270-4137 |
IngestDate | Thu Nov 21 22:50:36 EST 2024 Sat Sep 28 07:45:47 EDT 2024 Sun Oct 22 16:07:21 EDT 2023 Sat Aug 24 01:01:55 EDT 2024 Mon Nov 18 03:20:00 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | Histological grading Andrology Nephrology Urinary system disease Toll like receptor 4 tumor immunology Prostate disease Gynecology Toll-like receptor 4 Gleason grade Inflammation Malignant tumor Association Immunology Urogenital system Male genital diseases Prostate cancer Prostate Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3954-d6e29aac8ad1bd379ffe43decad70539ac1b7eacefc69ef4785ddc43617bfd8c3 |
Notes | Agencia Nacional de Promoción Científica y Tecnológica (ANPCYT) - No. PICT 2002 11944; No. PICT 2006 02369 istex:23B0D9F1BFB840A8770E8077A986F68E83F11E3F ark:/67375/WNG-SMLD1RJV-H Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET) - No. PEI 6557 ArticleID:PROS20984 |
PMID | 19496069 |
PageCount | 11 |
ParticipantIDs | crossref_primary_10_1002_pros_20984 pubmed_primary_19496069 pascalfrancis_primary_21831154 wiley_primary_10_1002_pros_20984_PROS20984 istex_primary_ark_67375_WNG_SMLD1RJV_H |
PublicationCentury | 2000 |
PublicationDate | 15 September 2009 |
PublicationDateYYYYMMDD | 2009-09-15 |
PublicationDate_xml | – month: 09 year: 2009 text: 15 September 2009 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States |
PublicationTitle | The Prostate |
PublicationTitleAlternate | Prostate |
PublicationYear | 2009 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004; 171: S36-S40. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005; 65: 11771-11778. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007; 67: 774-781. Quintar AA, Roth FD, De Paul AL, Aoki A, Maldonado CA. Toll-like receptor 4 in rat prostate: Modulation by testosterone and acute bacterial infection in epithelial and stromal cells. Biol Reprod 2006; 75: 664-672. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007; 100: 733-737. Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97: 525-532. Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 352-355. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-3197. Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS. Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun 2009; 1: 59-68. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: A double-edged sword. Oncogene 2008; 27: 218-224. Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64: 2918-2922. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-364. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007; 67: 10519-10527. Nickel JC, Moon T. Chronic bacterial prostatitis: An evolving clinical enigma. Urology 2005; 66: 2-8. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 2008; 9: 361-368. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002; 21: 3-16. Tanner MA, Shoskes D, Shahed A, Pace NR. Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and "nonbacterial" prostatitis. J Clin Microbiol 1999; 37: 1863-1870. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, Morrison SG, Morrison RP, Arditi M. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168: 1435-1440. Muthukuru M, Jotwani R, Cutler CW. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun 2005; 73: 687-694. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-2859. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium prostate. Cancer Res 1999; 59: 5002-5011. Chen Q, Fischer A, Reagan JD, Yan L, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci 1995; 92: 4337-4341. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13: 72-79. Lee JW, Choi JJ, Seo ES, Kim MJ, Kim WY, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 2007; 46: 941-947. Gatti G, Rivero V, Motrich RD, Maccioni M. Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and pro-inflammatory mediators upon LPS stimulation. J Leukoc Biol 2006; 79: 989-998. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, Hantzschel H, Michel BA, Gay RE, Gay S, Kyburz D. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172: 1256-1265. Nolte MA, Leibundgut-Landmann S, Joffre O, Reis e Sousa C. Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo. J Exp Med 2007; 204: 1487-1495. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-346. Smith MF Jr, Mitchell A, Li G, Ding S, Fitzmaurice AM, Ryan K, Crowe S, Goldberg JB. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem 2003; 278: 32552-32560. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-167. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008; 18: 315-319. Chicoine MR, Zahner M, Won EK, Kalra RR, Kitamura T, Perry A, Higashikubo R. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 2007; 60: 372-380. Pulai JI, Chen H, Im HJ, Kumar S, Hanning C, Hegde PS, Loeser RF. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005; 174: 5781-5788. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206. Mackern-Oberti JP, Maccioni M, Cuffini C, Gatti G, Rivero VE. Susceptibility of prostate epithelial cells to Chlamydia muridarum infection and their role in innate immunity by recruitment of intracellular Toll-like receptors 4 and 2 and MyD88 to the inclusion. Infect Immun 2006; 74: 6973-6981. König JE, Senge T, Allhoff EP, König W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004; 58: 121-129. Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 2008; 18: 300-305. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31. 2004; 64 2006; 74 1995; 92 2006; 75 2007; 204 2005; 174 2006; 79 2008; 18 1999; 49 2007; 100 2002; 13 1993; 85 2008; 9 2004; 5 2005; 65 2003; 278 2005; 66 2007; 16 2007; 178 2004; 58 2002; 168 2004; 172 2002; 21 1999; 37 2008; 27 1999; 59 2004; 171 2005; 73 2005; 97 2007; 7 2007; 60 2007; 44 2009; 1 2007; 67 2007; 46 2003; 21 e_1_2_1_41_2 e_1_2_1_40_2 e_1_2_1_22_2 e_1_2_1_23_2 e_1_2_1_20_2 e_1_2_1_21_2 e_1_2_1_26_2 e_1_2_1_27_2 e_1_2_1_24_2 e_1_2_1_25_2 e_1_2_1_28_2 e_1_2_1_29_2 Olumi AF (e_1_2_1_38_2) 1999; 59 e_1_2_1_6_2 e_1_2_1_30_2 e_1_2_1_7_2 e_1_2_1_4_2 e_1_2_1_5_2 e_1_2_1_2_2 e_1_2_1_11_2 e_1_2_1_34_2 e_1_2_1_3_2 e_1_2_1_12_2 e_1_2_1_33_2 e_1_2_1_32_2 e_1_2_1_10_2 e_1_2_1_31_2 e_1_2_1_15_2 e_1_2_1_16_2 e_1_2_1_37_2 e_1_2_1_13_2 e_1_2_1_36_2 e_1_2_1_14_2 e_1_2_1_35_2 e_1_2_1_19_2 e_1_2_1_8_2 e_1_2_1_17_2 e_1_2_1_9_2 e_1_2_1_18_2 e_1_2_1_39_2 |
References_xml | – volume: 16 start-page: 352 year: 2007 end-page: 355 article-title: Toll‐like receptor 4 genetic variation and advanced prostate cancer risk publication-title: Cancer Epidemiol Biomarkers Prev – volume: 85 start-page: 200 year: 1993 end-page: 206 article-title: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer publication-title: J Natl Cancer Inst – volume: 67 start-page: 10519 year: 2007 end-page: 10527 article-title: Activation of Toll‐like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo publication-title: Cancer Res – volume: 18 start-page: 315 year: 2008 end-page: 319 article-title: Inflammation, infection, and prostate cancer publication-title: Curr Opin Urol – volume: 58 start-page: 121 year: 2004 end-page: 129 article-title: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer publication-title: Prostate – volume: 59 start-page: 5002 year: 1999 end-page: 5011 article-title: Carcinoma‐associated fibroblasts direct tumor progression of initiated human prostatic epithelium prostate publication-title: Cancer Res – volume: 74 start-page: 6973 year: 2006 end-page: 6981 article-title: Susceptibility of prostate epithelial cells to Chlamydia muridarum infection and their role in innate immunity by recruitment of intracellular Toll‐like receptors 4 and 2 and MyD88 to the inclusion publication-title: Infect Immun – volume: 7 start-page: 256 year: 2007 end-page: 269 article-title: Inflammation in prostate carcinogenesis publication-title: Nat Rev Cancer – volume: 60 start-page: 372 year: 2007 end-page: 380 article-title: The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll‐like receptor 4 publication-title: Neurosurgery – volume: 9 start-page: 361 year: 2008 end-page: 368 article-title: TRAM couples endocytosis of Toll‐like receptor 4 to the induction of interferon‐beta publication-title: Nat Immunol – volume: 204 start-page: 1487 year: 2007 end-page: 1495 article-title: Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo publication-title: J Exp Med – volume: 100 start-page: 733 year: 2007 end-page: 737 article-title: The role of inflammation and infection in the pathogenesis of prostate carcinoma publication-title: BJU Int – volume: 79 start-page: 989 year: 2006 end-page: 998 article-title: Prostate epithelial cells can act as early sensors of infection by up‐regulating TLR4 expression and pro‐inflammatory mediators upon LPS stimulation publication-title: J Leukoc Biol – volume: 13 start-page: 72 year: 2002 end-page: 79 article-title: Meta‐analysis of measures of sexual activity and prostate cancer publication-title: Epidemiology – volume: 178 start-page: 3186 year: 2007 end-page: 3197 article-title: TLR9 expression and function is abolished by the cervical cancer‐associated human papillomavirus type 16 publication-title: J Immunol – volume: 64 start-page: 2918 year: 2004 end-page: 2922 article-title: Sequence variants of toll‐like receptor 4 are associated with prostate cancer risk: Results from the Cancer Prostate in Sweden Study publication-title: Cancer Res – volume: 172 start-page: 1256 year: 2004 end-page: 1265 article-title: Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll‐like receptor 2 ligands publication-title: J Immunol – volume: 21 start-page: 3 year: 2002 end-page: 16 article-title: The diet, prostate inflammation, and the development of prostate cancer publication-title: Cancer Metastasis Rev – volume: 278 start-page: 32552 year: 2003 end-page: 32560 article-title: Toll‐like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori‐induced NF‐kappa B activation and chemokine expression by epithelial cells publication-title: J Biol Chem – volume: 174 start-page: 5781 year: 2005 end-page: 5788 article-title: NF‐kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments publication-title: J Immunol – volume: 1 start-page: 59 year: 2009 end-page: 68 article-title: Toll‐like receptor‐9 expression is inversely correlated with estrogen receptor status in breast cancer publication-title: J Innate Immun – volume: 65 start-page: 11771 year: 2005 end-page: 11778 article-title: Sequence variants of Toll‐like receptor 4 and susceptibility to prostate cancer publication-title: Cancer Res – volume: 97 start-page: 525 year: 2005 end-page: 532 article-title: Sequence variants in Toll‐like receptor gene cluster (TLR6‐TLR1‐TLR10) and prostate cancer risk publication-title: J Natl Cancer Inst – volume: 168 start-page: 1435 year: 2002 end-page: 1440 article-title: Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll‐like receptor 4 and MD2 in a MyD88‐dependent pathway publication-title: J Immunol – volume: 7 start-page: 353 year: 2007 end-page: 364 article-title: The family of five: TIR‐domain‐containing adaptors in Toll‐like receptor signalling publication-title: Nat Rev Immunol – volume: 92 start-page: 4337 year: 1995 end-page: 4341 article-title: Oxidative DNA damage and senescence of human diploid fibroblast cells publication-title: Proc Natl Acad Sci – volume: 49 start-page: 8 year: 1999 end-page: 31 article-title: Cancer statistics, 1999 publication-title: CA Cancer J Clin – volume: 66 start-page: 2 year: 2005 end-page: 8 article-title: Chronic bacterial prostatitis: An evolving clinical enigma publication-title: Urology – volume: 44 start-page: 2850 year: 2007 end-page: 2859 article-title: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance publication-title: Mol Immunol – volume: 46 start-page: 941 year: 2007 end-page: 947 article-title: Increased toll‐like receptor 9 expression in cervical neoplasia publication-title: Mol Carcinog – volume: 171 start-page: S36 year: 2004 end-page: S40 article-title: Epidemiology of inflammation and prostate cancer publication-title: J Urol – volume: 27 start-page: 218 year: 2008 end-page: 224 article-title: TLR signaling by tumor and immune cells: A double‐edged sword publication-title: Oncogene – volume: 37 start-page: 1863 year: 1999 end-page: 1870 article-title: Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and “nonbacterial” prostatitis publication-title: J Clin Microbiol – volume: 18 start-page: 300 year: 2008 end-page: 305 article-title: Increased expression of Toll‐like receptor 5 during progression of cervical neoplasia publication-title: Int J Gynecol Cancer – volume: 27 start-page: 161 year: 2008 end-page: 167 article-title: Toll‐like receptor 9 (TLR9) agonists in the treatment of cancer publication-title: Oncogene – volume: 67 start-page: 774 year: 2007 end-page: 781 article-title: Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro publication-title: Prostate – volume: 75 start-page: 664 year: 2006 end-page: 672 article-title: Toll‐like receptor 4 in rat prostate: Modulation by testosterone and acute bacterial infection in epithelial and stromal cells publication-title: Biol Reprod – volume: 21 start-page: 335 year: 2003 end-page: 346 article-title: Toll‐like receptors publication-title: Annu Rev Immunol – volume: 73 start-page: 687 year: 2005 end-page: 694 article-title: Oral mucosal endotoxin tolerance induction in chronic periodontitis publication-title: Infect Immun – volume: 5 start-page: 987 year: 2004 end-page: 995 article-title: Toll‐like receptor control of the adaptive immune responses publication-title: Nat Immunol – ident: e_1_2_1_5_2 doi: 10.1097/01.ju.0000108131.43160.77 – ident: e_1_2_1_19_2 doi: 10.4049/jimmunol.172.2.1256 – ident: e_1_2_1_36_2 doi: 10.4049/jimmunol.178.5.3186 – ident: e_1_2_1_40_2 doi: 10.1128/IAI.00593-06 – ident: e_1_2_1_20_2 doi: 10.1093/jnci/85.3.200 – ident: e_1_2_1_34_2 doi: 10.1111/j.1525-1438.2007.01008.x – ident: e_1_2_1_15_2 doi: 10.1189/jlb.1005597 – ident: e_1_2_1_3_2 doi: 10.1097/MOU.0b013e3282f9b3b7 – ident: e_1_2_1_9_2 doi: 10.1038/ni1112 – ident: e_1_2_1_28_2 doi: 10.1038/sj.onc.1210911 – volume: 59 start-page: 5002 year: 1999 ident: e_1_2_1_38_2 article-title: Carcinoma‐associated fibroblasts direct tumor progression of initiated human prostatic epithelium prostate publication-title: Cancer Res contributor: fullname: Olumi AF – ident: e_1_2_1_25_2 doi: 10.1073/pnas.92.10.4337 – ident: e_1_2_1_2_2 doi: 10.3322/canjclin.49.1.8 – ident: e_1_2_1_22_2 doi: 10.1074/jbc.M305536200 – ident: e_1_2_1_6_2 doi: 10.1111/j.1464-410X.2007.07091.x – ident: e_1_2_1_12_2 doi: 10.1158/0008-5472.CAN-05-2078 – ident: e_1_2_1_14_2 doi: 10.1093/jnci/dji070 – ident: e_1_2_1_32_2 doi: 10.1227/01.NEU.0000249280.61761.2E – ident: e_1_2_1_39_2 doi: 10.1095/biolreprod.106.053967 – ident: e_1_2_1_24_2 doi: 10.1023/A:1020110718701 – ident: e_1_2_1_37_2 doi: 10.1159/000151602 – ident: e_1_2_1_35_2 doi: 10.1002/mc.20325 – ident: e_1_2_1_10_2 doi: 10.1084/jem.20070325 – ident: e_1_2_1_7_2 doi: 10.1146/annurev.immunol.21.120601.141126 – ident: e_1_2_1_16_2 doi: 10.1002/pros.10317 – ident: e_1_2_1_18_2 doi: 10.4049/jimmunol.174.9.5781 – ident: e_1_2_1_29_2 doi: 10.1038/sj.onc.1210904 – ident: e_1_2_1_23_2 doi: 10.1097/00001648-200201000-00012 – ident: e_1_2_1_26_2 doi: 10.1016/j.urology.2004.12.028 – ident: e_1_2_1_21_2 doi: 10.4049/jimmunol.168.3.1435 – ident: e_1_2_1_27_2 doi: 10.1128/JCM.37.6.1863-1870.1999 – ident: e_1_2_1_17_2 doi: 10.1128/IAI.73.2.687-694.2005 – ident: e_1_2_1_8_2 doi: 10.1038/nri2079 – ident: e_1_2_1_30_2 doi: 10.1016/j.molimm.2007.01.022 – ident: e_1_2_1_11_2 doi: 10.1158/0008-5472.CAN-03-3280 – ident: e_1_2_1_13_2 doi: 10.1158/1055-9965.EPI-06-0429 – ident: e_1_2_1_33_2 doi: 10.1158/0008-5472.CAN-07-0079 – ident: e_1_2_1_4_2 doi: 10.1038/nrc2090 – ident: e_1_2_1_31_2 doi: 10.1002/pros.20562 – ident: e_1_2_1_41_2 doi: 10.1038/ni1569 |
SSID | ssj0010002 |
Score | 2.2275393 |
Snippet | BACKGROUND
Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll‐like receptors (TLRs) compose a family of... Chronic inflammation has been postulated to be an important driving force to prostate carcinoma. Toll-like receptors (TLRs) compose a family of receptors... |
SourceID | crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1387 |
SubjectTerms | Adenocarcinoma - immunology Adenocarcinoma - pathology Adenocarcinoma - physiopathology Biological and medical sciences Cell Line, Tumor Chemokines - genetics Cytokines - genetics Gene Expression Regulation, Neoplastic Gleason grade Gynecology. Andrology. Obstetrics Humans inflammation Male Male genital diseases Medical sciences Nephrology. Urinary tract diseases Prostate - pathology Prostate - physiology prostate cancer Prostatic Neoplasms - immunology Prostatic Neoplasms - pathology Prostatic Neoplasms - physiopathology Prostatitis - immunology Prostatitis - pathology Prostatitis - physiopathology Severity of Illness Index Signal Transduction - immunology Toll-like receptor 4 Toll-Like Receptor 4 - genetics Toll-Like Receptor 4 - metabolism tumor immunology Tumors Tumors of the urinary system Up-Regulation - immunology Urinary tract. Prostate gland |
Title | Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer |
URI | https://api.istex.fr/ark:/67375/WNG-SMLD1RJV-H/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpros.20984 https://www.ncbi.nlm.nih.gov/pubmed/19496069 |
Volume | 69 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB5aF0IvbR5tqqYxCyk9FERsaaXVQi-hcWJC4pjYbXoTq32ASVCCZYOP_Qn9jf0lmVk5cnIJhBwEOuxKy87rm318A_C1Y7jqSI32rRMecoPpjtIqQl3G4CVc6rgnq-6PxOBPdtgjmpwf93dhan6IZsGNLMP7azJwVVT7K9JQdDBEty0zIgPFNMHf34iHzRYC2bpfYBGdED21aLhJo_1V10fR6A1N7IJOR6oKJ8jVlS0ehKaH8NXHn6P3Lxv5Orxb4k52UCvKBryy5SasnS131reg6i2WR2JLduPYGNXj_99_15Mry9An2ltMzRlnk5IhYGT0aQKpzBcAYfRMZhVTK1EzWt_1bTHyWiqQR19t-mnStekH-HXUG__sh8uCDKGOJYrSpDaSSulMmW5hYiGdszw2Visj0Jil0t1CoCe3TqfSOi6yxBjNY0RJhTOZjj9Cq7wp7SdgiCTjlEvt6DZ-YnQW6azjjMycS4UoogD27gWT39a8G3nNsBzlNNjcz18A37zMmiZqekUn1USSXw6O89HZ6WH34uR33g-g_UioTQdCiMRIFMB2LeXV3ySn7E4G8N0L84lh5MOL85F_-_ycxjvwtt6bkmE3-QKt2XRud-F1ZeZtr8p3Nrj46g |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxEB7xkEovQFvaLuVhiaqHSiuSXe96fegBQSCUJEUkLb1Zjh9SRLWgBCSO_Qn9jfwSZrxhA5dKiMNKe7B3Lc_r89j-BuBzw3LdkAbt22Q85haXO9roBHUZg5fwueeBrLrdF73fxUGLaHK-PdyFqfgh6oQbWUbw12TglJDenbGGoochvm1Z8HlY5DlqIt3gSE_rTQSy9pBiEY0YfbWo2UmT3VnfJ_Fokab2ls5H6glOka9qWzwKTo8BbIhAhysvHPsqLE-hJ9urdOUNzLnyLbzqTjfX38GkdTs9FVuyS88GqCF3f__9GV04hm7RXeHqnHE2KhliRkafJpzKQg0QRs_oesL0TNqMUryhLQZfRzXy6Kt1P0PqNl6Dn4etwX47ntZkiE0qUZo2d4nU2hTaNoc2FdJ7x1PrjLYC7Vlq0xwKdObOm1w6z0WRWWt4ikBp6G1h0vewUF6W7iMwBJNpzqXxdCE_s6ZITNHwVhbe50IMkwh2HiSjrirqDVWRLCeKBqvC_EXwJQitbqLHF3RYTWTqvHek-t3OQfPs-y_VjmDriVTrDgQSiZQogg-VmGd_k5wWeDKCr0Ga_xmGOj370Q9v689pvA1L7UG3ozrHvZNP8LraqpJxM9uAhevxjduE-Ym92Qp6fQ_dFf0S |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JTxsxFH4qIKFeWLoOWy2Beqg0IpnxjMcSF0SSBgppRGjLzXK8SBFoiBKQOPIT-hv7S3jPEyZwqVT1MJIPtsfy2z5v3wPYa1iuG9KgfZuMx9zickcbnaAuY_ASPvc8kFV3B6J3WbTaRJNz8PQWpuKHqDfcyDKCvyYDH1u_PycNRQdDdNuy4AuwxBGHE3N-mvbrMwQy9rDDIhoxumpRk5Mm-_O2L8LREs3sPV2P1FOcIV-ltngWm57j1xCAOqv_N_Q1WJkBT3ZYaco6vHLlG1g-mx2tv4Vp-352J7ZkN55doH78efh9PbpyDJ2iG-PanHE2KhkiRkZdE0plIQMIo290O2V6LmtGG7yhLoZeRxnyqNe6nSFlm7yDH532xVE3nmVkiE0qUZY2d4nU2hTaNoc2FdJ7x1PrjLYCrVlq0xwKdOXOm1w6z0WRWWt4ijBp6G1h0vewWN6U7iMwhJJpzqXx9Bw_s6ZITNHwVhbe50IMkwh2nwSjxhXxhqoolhNFg1Vh_iL4HGRWV9GTK7qqJjL1q_dVDc5OW83zk5-qG8HOC6HWDQgiEiVRBB8qKc__Jjkt72QEX4Iw_zIM1T__PgiljX-p_AmW-62OOj3ufduE19U5lYyb2RYs3k7u3DYsTO3dTtDqR9l_-7g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+of+Toll%E2%80%90like+receptor+4+in+the+prostate+gland+and+its+association+with+the+severity+of+prostate+cancer&rft.jtitle=The+Prostate&rft.au=Gatti%2C+Gerardo&rft.au=Quintar%2C+Amado+A.&rft.au=Andreani%2C+Virginia&rft.au=Nicola%2C+Juan+P.&rft.date=2009-09-15&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0270-4137&rft.eissn=1097-0045&rft.volume=69&rft.issue=13&rft.spage=1387&rft.epage=1397&rft_id=info:doi/10.1002%2Fpros.20984&rft.externalDBID=10.1002%252Fpros.20984&rft.externalDocID=PROS20984 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-4137&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-4137&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-4137&client=summon |